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Background: Findings related to the influence of the −160C→ A promoter polymorphism and haplotypes of the
E-cadherin (CDH1) gene have not been consistent in previous studies regarding the risk for sporadic gastric cancer.
Investigators in most previous studies detected those genotypes using restriction fragment length polymorphism
analysis. Therefore, we conducted a case–control study to investigate the association of the CDH1 − 160C→ A
promoter polymorphism and haplotypes for cancer risk related to sporadic diffuse and intestinal gastric cancer by
direct sequencing analysis.
Methods: We included 107 diffuse gastric cancer cases, 60 intestinal gastric cancer cases and 134 controls. The
genotypic polymorphisms in the −160 promoter region, exons and intron–exon boundaries of CDH1 were detected
by direct sequencing analysis. Genotype frequencies were compared. The CDH1 − 160C→ A promoter
polymorphism and four polymorphisms (48 + 6 T→ C, 2076C→ T, 2253C→ T and 1937–13 T→ C) were included
in the haplotype analyses, which were estimated using the expectation–maximization algorithm.
Results: Compared to controls, the frequency of the −160A allele was significantly higher in diffuse gastric cancer
cases (P = 0.005), but it was not significantly different in intestinal gastric cancer cases (P = 0.119). Two sets of three-marker
haplotypes (−160C→ A, 48 + 6 T→ C, 2076C→ T and −160C→ A, 1937–13 T→ C, 2253C→ T) were associated with the
risk of diffuse gastric cancer (P = 0.011 and P = 0.042, respectively).
Conclusion: Based on direct sequencing analysis, our findings suggest that the CDH1− 160C→ A promoter
polymorphism and haplotypes play significant roles in cancer risk for sporadic diffuse gastric cancer, but not for intestinal
gastric cancer, in a Taiwanese population.
Keywords: CDH1, Direct sequencing, Haplotypes, Single-nucleotide polymorphisms, Sporadic diffuse and intestinal gastric
cancerBackground
E-cadherin (encoded by the CDHI gene [dbSNP:
NC_000016.9]) is a member of a family of transmembrane
glycoproteins expressed in epithelial cells and is responsible
for calcium-dependent cell-to-cell adhesion [1-3]. Loss of
cell adhesion may contribute to loss of growth contact in-
hibition, which is an early step in the neoplastic process* Correspondence: dlyaochi@gmail.com
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unless otherwise stated.[4,5]. Furthermore, loss of cadherin activity may result in
cancer cell detachment and metastasis [6]. Hence CDHI is
considered to be a tumor suppressor gene.
A C/A single-nucleotide polymorphism (SNP) at
the −160 position of the CDH1 promoter region has
been reported to result in downregulation of the tran-
scription of this gene in a prostate cancer cell line,
DU145, such that the A allele at this site decreased
transcriptional efficiency by 68% compared with the C allele
[7]. Therefore, the −160A allele variant has been considered
to be a potential genetic marker for susceptibility to cancer.
However, findings related to the influence of the −160C→. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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herin (CDH1) gene have not been consistent in previous
studies regarding the risk for sporadic gastric cancer [8-16].
Some studies have reported that the CDH1 − 160C→A
promoter polymorphism was not found to be associated
with the risk of gastric cancer [8-11], and others have re-
ported that the −160A allele increased the risk for diffuse
gastric cancer [12,13]. Conversely, two studies in Asian
populations reported that the −160A allele decreased the
risk of gastric cancer [15,16].
The genotypes of the −160C→A promoter polymorph-
ism in most of the previous studies were detected by re-
striction fragment length polymorphism (RFLP) analysis
[8-13,15,16]. RFLP analysis is an indirect method applied
extensively in the past [17]. However, it involves a manual
process that is based on gel-based processing techniques
and the results it produces are subjectively evaluated by
direct observation. In contrast, direct sequencing is a stan-
dardized procedure, and the results are processed by a
computer [18].
By literature review, we compared the CDH1 − 160A
allele frequency in controls in studies in which RFLP
analysis was used, and the −160A allele frequency in
healthy samples reported by HapMap based on direct
sequencing derived from the National Center for Bio-
technology Information dbSNP Short Genetic Varia-
tions online database [19]. The frequency of the −160A
allele was calculated using the formula CA% × ½ +
AA%, where CA is the C and A alleles and AA is the
double A alleles. Humar et al. reported that the fre-
quency of the −160A allele in controls in an Italian
population was 23.6% [12], and Corso et al. reported a
frequency of 32.05% in a different Italian population
[11]. In a study by Pharoah et al., the frequency of
the −160A allele was found to be 30% for Canadian,
German and Portuguese populations [8]. Park et al.
reported that the frequency of the −160A allele in con-
trols in a Korean population was 23% [9]. Lu et al.
reported that the frequency of the −160A allele was 24.3%
for Chinese individuals in Jiangsu Province, China [10].
Medina-Franco et al. reported that the frequency of the
−160A allele was 24.35% in a Mexican population [13]. Wu
et al. reported that the frequency of the -160A allele was
33.67% in a Taiwanese population [15]. Kuraoka et al. re-
ported that the frequency of the −160A allele was 35% in a
Japanese population [16]. The HapMap database, however,
gives information based on direct sequencing that the fre-
quency of the −160A allele in healthy samples is 26.0% for
Europeans in Italy, 25.2% for Han Chinese in Beijing, 19.9%
for Japanese in Tokyo and 15.0% for Africans in Nigeria
[19]. In aforementioned studies in which RFLP analysis
was used, the reported frequencies of the −160A allele
in controls were diverse within the same ethnic groups,
and some were much higher than the values in theHapMap database. Therefore, genotype detection by RFLP
analysis in some of previous studies might be inaccur-
ate, which might contribute to the inconsistency of re-
sults in previous studies. Tanahashi et al. and Davis
et al. also reported that RFLP analysis was less accurate
than direct sequencing in their studies [20,21]. How-
ever, researchers in many studies have suggested that
environmental factors, lifestyles and ethnic differences
might account for opposite directions in associations
of the CDH1 − 160C→ A polymorphism with gastric
cancer among some Asian and Caucasian studies
[8-14,22,23]. Gene-based haplotypes, which are collec-
tions of SNPs located throughout the functional re-
gions of candidate genes, may have greater power than
any individual polymorphism in influencing a clinical
response [24].
In one study of haplotype analysis using RFLP methods,
the investigators suggested that the CDH1 − 160C→A
polymorphism might be in linkage disequilibrium with
other distinct CDH1 polymorphisms in sporadic diffuse
gastric cancer [12] Researchers in another study using
direct sequencing reported a statistically nonsignificant
risk of −160C→A polymorphism containing haplotypes
associated with gastric cancer without differentiation of
histopathologic subgroups [14]. Furthermore, diffuse and
intestinal types of gastric cancer are different in terms of
their epidemiology, etiology, pathogenesis and behavior
[25]. Therefore, we investigated the influence of the
CDH1 − 160C→A promoter polymorphism and haplo-
types on risk for diffuse and intestinal gastric cancer sep-
arately by direct sequencing.Methods
Patients and samples
Eligible cases comprised 167 sporadic gastric cancer pa-
tients who had undergone surgical treatment between 2001
and 2005 in the Division of General Surgery, Department
of Surgery, Tri-Service General Hospital, Taipei, Taiwan. All
of the Taiwanese patients were Han Chinese, but no aborig-
ines were included, as they belong to a different ethnic
group that account for only 0.02% of the population in
Taiwan. None of the patients had familial gastric cancer. All
patient DNA obtained from the noncancerous gastric epi-
thelia of resected specimens were stored in liquid nitrogen.
Control DNA was obtained from the peripheral blood
of 134 healthy individuals who attended general health
checkup including upper gastrointestinal tract endoscopy
in this hospital. The study participants provided written
informed consent prior to participation. The study was
approved by the Institutional Review Board of the Tri-
Service General Hospital. All surgical samples were
classified into diffuse and intestinal types according to
the Laurén criteria [25].
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expression
Specimens from paraffin blocks were cut into 5-μm
sections and stained with hematoxylin and eosin for
histological diagnosis. E-cadherin expression was evalu-
ated using a monoclonal antibody (Cappel, Aurora, OH,
USA) followed by a secondary antibody [26]. The signal
was detected using an avidin-biotin complex and a
3,3′-diaminobenzidine (DAB) kit (Vector Laboratories,
Burlingame, CA, USA). DAB produced a yellowish brown
stain if a sample was positive. If more than 90% of the
tumor cells showed intense membranous staining similar to
that of normal cells, the result was considered positive (++).
If the staining intensity was demonstrably reduced relative
to that of normal cells and/or if the staining pattern was
heterogeneous (10% to 90% positive), the result was re-
corded as weakly positive (+). If immunohistochemical ex-
pression was completely absent or positive in less than 10%
of the cells, the result was defined as negative (−).
Genotyping
DNA samples from all cases were extracted from non-
cancerous gastric epithelia. Control DNA samples were
isolated from peripheral blood lymphocytes by proteinase K
digestion and phenol-chloroform extraction. All CDH1
exons and the corresponding intron–exon boundaries of
case DNA and control DNA were amplified using primers
developed by Berx et al. [27]. The primers used to amplify
the −160 promoter region were described by Li et al. [7].
PCR was carried out in volumes of 25 μl containing 20 ng
of genomic DNA as a template, 2 mM MgSO4, 0.4 μM
sense and antisense primers, 0.25 mM deoxyribonucleotide
triphosphate, and buffer containing Taq DNA polymerase.
The amplification program was as follows: 40 cycles with a
denaturing temperature of 95°C for 30 seconds, annealing
for 30 seconds and extension at 72°C for 30 seconds in a
DNA thermal cycler. All amplified products were puri-
fied, and direct sequencing was performed using an
ABI PRISM 377 automated sequencer and an ABI PRISM
Dye Terminator Cycle Sequencing Kit (PerkinElmer,
Greenville, SC, USA).Figure 1 Immunohistochemical staining for E-cadherin. (a) E-cadherin-
diffuse type cancer.Statistical analysis
Stata 8 software (StataCorp, College Station, TX, USA)
was used to manage data and for statistical analyses. The
observed genotype frequencies were compared between
cases and controls using a χ2 test. Fisher’s exact test was
used to assess the genotype and allele distributions in
diffuse and intestinal type cases. The allelic distribution
was in Hardy-Weinberg equilibrium in the case and
control groups (P > 0.82). Genotype-specific risks were
estimated as the odds ratio (OR) with associated 95%
confidence interval (CI) by unconditional logistic regres-
sion. ORs were adjusted according to age and gender. A
P-value less than 0.05 was considered statistically signifi-
cant. The study power was 0.7758 to 0.9509 with an α of
0.05 [28]. The haplotype frequencies for various marker
combinations were estimated separately for the two
type cases and the controls by using an expectation-
maximization algorithm.Results
Characteristics of diffuse and intestinal type cases
The 134 controls were composed of 86 males and 48 fe-
males. Their mean age was 51.06 ± 13.04 years (range =
19 to 89 years). The 167 gastric cancer cases comprised
114 males and 53 females. Their mean age was 69.11 ±
13.04 years (range = 27 to 90 years). According to Laurén’s
classification system, 107 cases were of the diffuse type and
60 cases were of the intestinal type. The mean age of the
diffuse type cases was 66.87 ± 13.81 years (range = 27 to
90 years) and that of the intestinal type cases was 73.82 ±
9.76 years (range = 48 to 88 years). The mean age of the dif-
fuse type cases was approximately 7 years younger than
that of the intestinal type cases. No differences were ob-
served with respect to gender or TNM stages I to III in
these two types. There were significantly more diffuse gas-
tric cancer cases classified as stage IV. Reduced E-cadherin
expression (Figure 1) was more frequent in the diffuse type
cases than in the intestinal type cases. Comparison of the
characteristics between these two case types is summarized
in Table 1.positive (++) in intestinal type cancer. (b) E-cadherin-negative (−) in
Table 1 Comparison of clinicopathologic characteristics
between intestinal and diffuse type tumors
Characteristics Intestinal type,
n (%) (N = 60)
Diffuse type,
n (%) (N = 107)
P-value
Gender
Male 46 (76.7%) 68 (63.6%) 0.081a
Female 14 (23.3%) 39 (36.5%)
Age (yr)
Mean ± SD 73.82 ± 9.76 66.87 ± 13.81 0.0001b
TNM staging
Stage I 16 (26.7%) 16 (15.0%) 0.065c
Stage II 8 (13.3%) 24 (22.4%) 0.152c
Stage III 28 (46.7%) 35 (32.7%) 0.074c
Stage IV 8 (13.3%) 32 (30.0%) 0.016c
Reduced E-cadherin
expression
32 (53.3%) 93 (86.9%) <0.001c
aχ2 test. bt-test. cProportion test.
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The genotypes of the CDH1 − 160C→A (dbSNP:rs16260),
48 + 6 T→C (dbSNP:rs3743674), 2076C→T (dbSNP:
rs1801552), 2253C→T (dbSNP:rs33964119) and 1937–
13 T→C (dbSNP:rs2276330) polymorphisms detected byFigure 2 Genotypes of CDH1 polymorphisms detected by direct sequenc
48 + 6 T→ C. (c) Exon 13 polymorphism 2076C→ T. (d) Exon 14 polymorphismdirect sequencing in the cases and controls are shown
in Figure 2.Single-locus analysis in diffuse type cases
For promoter polymorphism −160C→A, the frequency
of the −160A allele was significantly higher in diffuse
type cases compared to the controls (P = 0.005). The OR
associated with the A allele was 1.750 (95% CI = 1.014 to
3.022) for CA heterozygotes and 4.375 (95% CI = 1.467
to 14.565) for AA homozygotes. For other four polymor-
phisms (48 + 6 T→ C, 2076C→ T, 1937–13 T→ C and
2253C→T), the genotype frequencies were not signifi-
cantly different between the diffuse type cases and the
controls (P = 0.441, 0.649, 0.147 and 0.982, respectively)
(Table 2).Single-locus analysis in intestinal type cases
In the intestinal type cases, no significant association with
disease was found for any of the five polymorphisms
(−160C→A, 48 + 6 T→C, 2076C→T, 1937–13 T→C
and 2253C→T; P = 0.119, 0.329, 0.185, 0.889 and 0.375,
respectively).ing. (a) Promoter polymorphism −160C→A. (b) Intron 1 polymorphism
2253C→ T. (e) Intron 12 polymorphism 1937–13 T→ C.
Table 2 Genotype frequencies of CDH1 polymorphisms in diffuse gastric cancer cases and controls
Variant Cases vs.controls n (%) n (%) n (%) n (%)
Statistical tests Fisher’s
exact testχ2 test P-value
Promoter CC CA AA Total 10.7858 0.005 0.005
−160C→ A Diffuse 48 44.86% 44 41.12% 15 15.00% 107 100.00%
Controls 84 62.69% 44 32.84% 6 4.48% 134 100.00%
Odds ratioa 1 1.750 (1.014 to 3.022) 4.375 (1.467 to 14.565)
Intron 1 TT TC CC 1.6397 0.441 0.489
48 + 6 T→ C Diffuse 71 66.36% 32 29.91% 4 3.74% 107 100.00%
Controls 92 68.66% 33 24.63% 9 6.72% 134 100.00%
Odds Ratioa 1 1.257 (0.677 to 2.328) 0.576 (0.125 to 2.170)
Exon 13 CC CT TT 0.8651 0.649 0.641
2076C→ T Diffuse 45 42.06% 48 44.83% 14 13.08% 107 100.00%
Controls 55 41.05% 66 49.25% 13 9.70% 134 100.00%
Odds ratioa 1 0.889 (0.499 to 1.584) 1.136 (0.514 to 3.381)
Intron 12 TT TC CC 2.100 0.147 0.182
1937-13 T→ C Diffuse 89 83.18% 18 16.82% 0 0.00% 107 100.00%
Controls 120 89.55% 14 10.45% 0 0.00% 134 100.00%
Odds ratioa 1 1.734 (0.766 to 3.976) to
Exon 14 CC CT TT 0.037 0.982 1.000
2253C→ T Diffuse 89 83.18% 17 15.89% 1 0.93% 107 100.00%
Controls 111 82.84% 22 16.42% 1 0.75% 134 100.00%
Odds ratioa 1 0.964 (0.451 to 1.842) 1.247 (0.016 to 98.766)
aAdjusted for age and sex.
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A three-marker haplotype (−160C→A, 48 + 6 T→C,
2076C→T) showed a significant association with disease
and the ATC, ACC haplotypes were found to be associated
with increased risk for diffuse type cancer (Table 3). A differ-
ent three-marker haplotype (−160C→ A, 1937–13 T→C,
2253C→T) also exhibited a significant association with dis-
ease and the ATC haplotypes was associated with increased
risk for diffuse gastric cancer. The two other sets of three-
marker haplotypes (−160C→ A, 2076C→T, 2253C→T
and −160C→A, 48 + 6 T→C, 1937–13 T→C) exhibited
no significant association with disease (Table 3).
Haplotype analysis in intestinal type cases
In the intestinal type cases, no significant association
with disease was found for any of the four sets of
three-marker haplotypes (−160C→ A, 48 + 6 T→ C,
2076C→ T; −160C→ A, 1937–13 T→ C, 2253C→
T; −160C→A, 2076C→T, 2253C→T and −160C→ A,
48 + 6 T→C, 1937–13 T→C; P = 0.164, 0.319, 0.408 and
0.607, respectively).
Discussion
To detect SNP variations, both direct sequencing and RFLP
are suitable. RFLP is subject to experimental problems,however, such as incomplete digestion and relatively poor
resolution, resulting in misclassification of genotypic status.
Nevertheless, many previous studies have depended on
RFLP because it is cheaper and easy to perform. However,
the cost of direct sequencing has decreased significantly,
and regular automatic sequencing platforms are able to
provide reliable results easily. The use of sequencing in the
present study can be considered a major strength.
In this study, specimens were obtained from 167
Taiwanese patients with sporadic gastric cancer who
underwent surgical treatment. The patients with intes-
tinal gastric cancer are generally older, have more co-
morbidities and tend not to undergo surgical treatment,
which accounts for more diffuse gastric cancer cases
than intestinal gastric cancer cases. Although we used
an acceptable number of cases with statistical power,
the sample size was still relatively small. Further studies
including more cases are needed.
The frequency of the A allele in the CDH1 − 160C→
A promoter polymorphism in this study was significantly
greater in diffuse type cases than in the controls. Humar
et al. [12] and Medina-Franco et al. [13] reported similar
results.
It has been suggested that CDH1 may contribute to
gastric cancer risk in a complex manner due to multiple
Table 3 CDH1 three-marker haplotype analysis in diffuse gastric cancer cases
Three polymorphisms Haplotype Cases (%) Controls (%) OR Lower 95% CI Upper 95% CI P-value
−160C→ A CTT 24.70 25 1.132 0.860 1.489 0.011
48 + 6 T→ C ATT 5.93 4.48 1.511 0.926 2.466
2076C→ T CCC 12.07 13.27 1.030 0.731 1.452
CTC 31.78 36.38 1
CCT 3.80 4.48 0.954 0.552 1.648
ATC 18.81 15.11 1.431 1.051 1.949
ACC 2.52 0.93 3.272 1.322 8.096
ACT 0.38 0.37 0.954 0.158 5.761
−160C→ A CTT 7.72 8.02 1.079 0.729 1.597 0.042
1937-13 T→ C ATT 1.41 0.75 2.073 0.732 5.872
2253C→ T CCC 3.20 3.36 1.075 0.599 1.929
CTC 61.22 67.53 1
CCT 0.21 0.19 0.691 0.062 7.648
ATC 23.34 18.47 1.4 1.078 1.819
ACC 2.86 16.79 0.184 0.111 0.306
ACT 0.04 0 – – –
−160C→ A CCT 1.62 14.93 0.108 0.055 0.212 0.096
2076C→ T ACT 0.09 0.19 0.691 0.058 7.227
2253C→ T CTC 37.54 42.91 0.909 0.703 1.176
CCC 26.88 27.99 1
CTT 6.31 6.72 0.987 0.628 1.551
ACC 6.23 4.66 1.406 0.862 2.293
ATC 19.97 15.49 1.332 0.971 1.827
ATT 1.37 0.56 2.341 0.771 7.111
−160C→ A CTC 53.84 58.79 0.904 0.470 1.739 0.103
48 + 6 T→ C ATC 22.01 17.91 1.21 0.613 2.389
1937-13 T→ C CCT 0.77 0.93 0.882 0.237 3.281
CTT 2.65 2.61 1
CCC 15.10 16.79 0.888 0.445 1.772
ATT 2.73 1.68 1.588 0.616 4.094
ACT 0.17 0 – – –
ACC 2.73 1.31 2.021 0.754 5.416
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the three-marker haplotype (−160C→A, 48 + 6 T→C,
2076C→T) was associated with diffuse gastric cancer
and suggested that haplotype ATT (−160A, 48 + 6 T,
2076 T) was a marker for diffuse gastric cancer susceptibil-
ity, whereas haplotype CTT had a protective effect [12].
We also found that the three-marker haplotype
(−160C→ A, 48 + 6 T→ C, 2076C→ T) was associated
with diffuse gastric cancer and the ATC and ACC hap-
lotypes were associated with increased risk. However,
the haplotype CTT had no protective effect on diffuse
gastric cancer which differs from that reported by Humar
et al. [12]. Furthermore, we found another three-markerhaplotype (−160C→A, 1937–13 T→C, 2253C→T) that
was associated with diffuse gastric cancer, and the ATC
haplotypes showed increased risk.
In the three-marker haplotype in this study (−160C→
A, 48 + 6 T→C, 2076C→T), the haplotype ATC, with
only one polymorphic variant (−160A) showed in-
creased diffuse gastric cancer risk. Therefore, with re-
spect to the CDH1 − 160C→ A polymorphism, the A
allele might result in a defect in gene transcription and
increased risk for diffuse type cancer. The ACC haplo-
type, with two polymorphic variants (−160A and 48 +
6C), exhibited a higher OR. This finding indicates that
the presence of two polymorphic variants in this
Chu et al. World Journal of Surgical Oncology 2014, 12:80 Page 7 of 8
http://www.wjso.com/content/12/1/80haplotype produces synergic effects related to cancer
risk.
Conclusions
We conclude that, based on direct sequencing analysis,
the −160C→A promoter polymorphism and the investi-
gated haplotypes play significant roles in the risk for spor-
adic diffuse gastric cancer, but not for intestinal gastric
cancer, in a Taiwanese population. In the future, additional
polymorphisms in other regions of the same gene, such as
the promoter region and splicing sites, should be evaluated,
and haplotype analysis should include additional polymor-
phisms for the purpose of increasing knowledge about how
combinations of polymorphisms can influence cancer risk.
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